Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: 13-g.... Fut, BaNosser

Feb 28, 2007 03:51AM

Feb 28, 2007 04:14AM

Feb 28, 2007 04:17AM

Feb 28, 2007 09:41AM

Guys,

This is part of what I posted, which is a table footnote from the last 10K. I highlighted the key points that address the question. S&L together are considered a single "Reporting Person." The latter highlighted sentence indicates that the "Reporting Person" is prohibited from exercising warrants if it would result in the "Reporting Person" owning more than 9.99% of the outstanding shares of common stock.

Hope this helps.

(7) Lincoln Ventures, LLC (“Lincoln”) and Swartz Private Equity, LLC (“SPE” and together with Lincoln, the “Reporting Person”) have shared voting power and shared dispositive power as to these shares. These amounts include 36,900,446 shares (in total between Lincoln and SPE, each of which hold warrants to purchase Common Stock of the Company) issuable upon exercise of outstanding warrants exercisable within 60 days of August 31, 2006. The documents governing the terms of such warrants contain a provision prohibiting Lincoln and SPE, as applicable, from exercising warrants for shares of Common Stock if doing so would result in the Reporting Person and their affiliates beneficially owning shares of Common Stock that represent more than 9.99% of the outstanding shares of Common Stock as determined under Section 13(d) of the Securities Exchange Act of 1934. This percentage assumes that Lincoln and SPE may be deemed to be affiliated and under common control.


Feb 28, 2007 10:59AM

Feb 28, 2007 11:09AM

Feb 28, 2007 11:10AM

Feb 28, 2007 12:25PM
Share
New Message
Please login to post a reply